An-Hua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
An-Hua Wang has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Jing-Ming Jia
Teaching and Research Department of Chinese Materia Medica Resources, College of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China
35 shared publications Xiao-Xu Gao
Teaching and Research Department of Chinese Materia Medica Resources, College of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China
8 shared publicationsDong-Dong Wang
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, PR China
7 shared publicationsJing-Ming Jia
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University
7 shared publicationsZi-Feng Guo
College of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
7 shared publications- Gaosheng Hu
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China
6 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Nature Communications
Darutigenol ameliorates experimental colitis via promoting Akkermansia muciniphila-mediated proline synthesis
- 29 October 2026
- Published by Springer Nature in Nature Communications
Open AccessDarutigenol ameliorates experimental colitis via promoting Akkermansia muciniphila-mediated proline synthesis
- Open Access
Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy
Liposomes represent one of the most extensively investigated nanocarriers in drug delivery. However, the efficient encapsulation of highly hydrophobic drugs like cabazitaxel (CTX) remains challenging due to their limited affinity with phospholipid bilayers. Herein, a lipid‐mimetic modification strategy was applied to improve the affinity between CTX and phospholipids. Briefly, octyldodecanol (ODA) which possessed a similar structure with the phospholipids' tail group was connected to CTX via disulfide bond to design a lipid‐mimetic CTX prodrug (CTX‐SS‐ODA). Thereafter, CTX prodrug‐loaded liposomes (CPLs) with varying drug‐to‐lipid ratios (1:10, 1:20, and 1:30) were successfully prepared and systematically evaluated. Compared with CTX liposomes, the CPLs had higher encapsulation efficiency, drug loading capacity and stability. More notably, a high drug‐to‐lipid ratio could reduce the particle concentration, thereby improving cell uptake and pharmacokinetic behavior. CPLs@D/L 1:10 with the highest drug‐to‐lipid ratio demonstrated remarkable pharmacokinetic improvements, exhibiting a 402‐fold increase in AUC 0‐72h compared to free CTX. This optimized formulation not only displayed potent antitumor activity but also maintained an excellent safety profile. Our findings underscore the effectiveness of lipid‐mimetic prodrug modification for liposome and emphasize the crucial role of drug‐to‐lipid ratio in developing high‐performance nanomedicines.
Open AccessTailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy
Liposomes represent one of the most extensively investigated nanocarriers in drug delivery. However, the efficient encapsulation of highly hydrophobic drugs like cabazitaxel (CTX) remains challenging due to their limited affinity with phospholipid bilayers. Herein, a lipid‐mimetic modification strategy was applied to improve the affinity between CTX and phospholipids. Briefly, octyldodecanol (ODA) which possessed a similar structure with the phospholipids' tail group was connected to CTX via disulfide bond to design a lipid‐mimetic CTX prodrug (CTX‐SS‐ODA). Thereafter, CTX prodrug‐loaded liposomes (CPLs) with varying drug‐to‐lipid ratios (1:10, 1:20, and 1:30) were successfully prepared and systematically evaluated. Compared with CTX liposomes, the CPLs had higher encapsulation efficiency, drug loading capacity and stability. More notably, a high drug‐to‐lipid ratio could reduce the particle concentration, thereby improving cell uptake and pharmacokinetic behavior. CPLs@D/L 1:10 with the highest drug‐to‐lipid ratio demonstrated remarkable pharmacokinetic improvements, exhibiting a 402‐fold increase in AUC 0‐72h compared to free CTX. This optimized formulation not only displayed potent antitumor activity but also maintained an excellent safety profile. Our findings underscore the effectiveness of lipid‐mimetic prodrug modification for liposome and emphasize the crucial role of drug‐to‐lipid ratio in developing high‐performance nanomedicines.
- 14 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158577
Lonicera trichosantha alleviates LPS-induced endometritis in mice by modulating the gut microbiota and host metabolism
- 14 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158577
Lonicera trichosantha alleviates LPS-induced endometritis in mice by modulating the gut microbiota and host metabolism
- 28 March 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 311, 118804
Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity
- 28 March 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 311, 118804
Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity
- 29 January 2026
- Published by Taylor & Francis in Natural Product Research
- p. 1-6
Isolation and antibacterial activity of three new flavonol compounds from Sophora flavescens
Three new flavonol compounds-kushenmin Q (1), kushenmin R (2), and kushenmin S (3)-along with two known compounds, 2S-sophoflavonoid B (4) and kushenol G (5), were isolated from the ethanol extract of Sophora flavescens root bark. Their structures were elucidated using UV spectroscopy, high-resolution electrospray ionisation mass spectrometry (HRESIMS), nuclear magnetic resonance (NMR), and comparison with published data. The antibacterial activity of compounds 1-5 was evaluated against eight bacterial strains (four Gram-positive and four Gram-negative) using the microbroth dilution method. Among the isolated compounds, the flavones 1, 3, and 4 exhibited significant antibacterial activity, with particularly strong effects against Gram-positive bacteria.
- 29 January 2026
- Published by Taylor & Francis in Natural Product Research
- p. 1-6
Isolation and antibacterial activity of three new flavonol compounds from Sophora flavescens
Three new flavonol compounds-kushenmin Q (1), kushenmin R (2), and kushenmin S (3)-along with two known compounds, 2S-sophoflavonoid B (4) and kushenol G (5), were isolated from the ethanol extract of Sophora flavescens root bark. Their structures were elucidated using UV spectroscopy, high-resolution electrospray ionisation mass spectrometry (HRESIMS), nuclear magnetic resonance (NMR), and comparison with published data. The antibacterial activity of compounds 1-5 was evaluated against eight bacterial strains (four Gram-positive and four Gram-negative) using the microbroth dilution method. Among the isolated compounds, the flavones 1, 3, and 4 exhibited significant antibacterial activity, with particularly strong effects against Gram-positive bacteria.
- 14 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121167
Exploring the mechanism of dihydromyricetin in alleviating psoriasis based on metabolomics, network pharmacology and experimental validation
- 14 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121167
Exploring the mechanism of dihydromyricetin in alleviating psoriasis based on metabolomics, network pharmacology and experimental validation
- 18 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability
CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural product library identified kushenmin K, a flavonoid with modest CDK inhibitory and antiproliferative activities. A strategy combining scaffold hopping with structure-guided design yielded HS-36, a novel oxazolylflavone derivative, which potently inhibited both CDK4 (IC50 = 18.9 nM) and CDK9 (IC50 = 4.2 nM). This dual activity effectively blocked cell cycle progression and triggered apoptosis by downregulating key downstream effectors, translating into potent antiproliferative activity. Notably, it maintained this potent activity even in CDK4/6 inhibitor-resistant cell models. Furthermore, HS-36 possessed an excellent pharmacokinetic profile, including good oral bioavailability (F = 41.8%), which enabled solid and well-tolerated in vivo antitumor efficacy (TGI = 68.8%) in a MV-4-11 xenograft model. This work not only presents HS-36 as a promising lead compound but also validates our rational approach to optimizing natural product scaffolds.
- 18 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability
CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural product library identified kushenmin K, a flavonoid with modest CDK inhibitory and antiproliferative activities. A strategy combining scaffold hopping with structure-guided design yielded HS-36, a novel oxazolylflavone derivative, which potently inhibited both CDK4 (IC50 = 18.9 nM) and CDK9 (IC50 = 4.2 nM). This dual activity effectively blocked cell cycle progression and triggered apoptosis by downregulating key downstream effectors, translating into potent antiproliferative activity. Notably, it maintained this potent activity even in CDK4/6 inhibitor-resistant cell models. Furthermore, HS-36 possessed an excellent pharmacokinetic profile, including good oral bioavailability (F = 41.8%), which enabled solid and well-tolerated in vivo antitumor efficacy (TGI = 68.8%) in a MV-4-11 xenograft model. This work not only presents HS-36 as a promising lead compound but also validates our rational approach to optimizing natural product scaffolds.
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (49) , 31312-31324
Tectoridin Derived from Puerariae Flos Alleviates Acute Ethanol-Induced Ataxia in Rats by Targeting the Adenosine A1 Receptor via Its Aglycone
As ingredients in vegetables, tea, and jelly, Puerariae Flos can relieve the discomfort caused by excessive ethanol intake. Here, we integrated liquid chromatography, gas chromatography, and in vivo microdialysis to explore the active components and mechanisms underlying Puerariae Flos-mediated attenuation of acute ethanol intoxication. Results demonstrate that Puerariae Flos flavonoid extract (PFF) and its active constituent tectoridin significantly enhance motor coordination in ethanol-exposed rats without altering the ethanol concentrations in blood or cerebellum. Notably, tectorigenin, a metabolite of tectoridin, crossed the blood-brain barrier (BBB) and exerted antiataxic effects by targeting adenosine A1 receptor (A1AR), as confirmed by molecular docking, cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS) assay, and GloSensor assay. We conclude that tectoridin in Puerariae Flos functions primarily via its metabolite tectorigenin, which targets cerebellar A1AR to alleviate ethanol-induced acute ataxia. This work provides novel mechanistic insight into Puerariae Flos for combating acute ethanol poisoning.
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (49) , 31312-31324
Tectoridin Derived from Puerariae Flos Alleviates Acute Ethanol-Induced Ataxia in Rats by Targeting the Adenosine A1 Receptor via Its Aglycone
As ingredients in vegetables, tea, and jelly, Puerariae Flos can relieve the discomfort caused by excessive ethanol intake. Here, we integrated liquid chromatography, gas chromatography, and in vivo microdialysis to explore the active components and mechanisms underlying Puerariae Flos-mediated attenuation of acute ethanol intoxication. Results demonstrate that Puerariae Flos flavonoid extract (PFF) and its active constituent tectoridin significantly enhance motor coordination in ethanol-exposed rats without altering the ethanol concentrations in blood or cerebellum. Notably, tectorigenin, a metabolite of tectoridin, crossed the blood-brain barrier (BBB) and exerted antiataxic effects by targeting adenosine A1 receptor (A1AR), as confirmed by molecular docking, cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS) assay, and GloSensor assay. We conclude that tectoridin in Puerariae Flos functions primarily via its metabolite tectorigenin, which targets cerebellar A1AR to alleviate ethanol-induced acute ataxia. This work provides novel mechanistic insight into Puerariae Flos for combating acute ethanol poisoning.
- Open Access
- 27 October 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 237
Pharmacodynamic basis and mechanism of action of processing waste from Sophora flavescens against multidrug-resistant methicillin-sensitive Staphylococcus aureus
- 27 October 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 237
Open AccessPharmacodynamic basis and mechanism of action of processing waste from Sophora flavescens against multidrug-resistant methicillin-sensitive Staphylococcus aureus